4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Hypothyroidism by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 73 ongoing clinical trials involving Hypothyroidism
Of the 73 trials,27 trials are in Phase II
Furthermore, 21 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Hypothyroidism by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Hypothyroidism, a Hormonal Disorder condition. The largest number of ongoing clinical trials for Hypothyroidism is conducted in the Asia-Pacific region. Middle East and Africa and Europe are among some of the other prominent regions engaged in Hypothyroidism-related drug trials.

Hypothyroidism related clinical trial sponsor

Shandong Provincial Hospital, Fuwai Hospital, Amsterdam University Medical Center, National Institute of Ayurveda and Shiraz University of Medical Sciences are among few notable clinical trial sponsors involved in Hypothyroidism. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Hypothyroidism

Levothyroxine sodium (Synthroid/ Thyronorm), Levothyroxine Sodium (Novothyrox, Euthyrox, Eutirox, Levothyrox) and Levothyroxine sodium (Thyradin-S / Levothyroxine Nycomed) are among the key marketed drugs involving Hypothyroidism.

Levothyroxine sodium (Synthroid/ Thyronorm) is a synthetic form of the thyroid hormone thyroxine (T4). It functions via Thyroid Hormone Receptor Agonist mechanism of action. Levothyroxine sodium is formulated as tablets for oral route of administration. Synthroid/ Thyronorm is used as a replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology. Levothyroxine sodium was first approved in 1996 and is marketed globally in the US, Brazil, Canada and India by several prominent pharma giants including AbbVie Inc.

Levothyroxine Sodium (Novothyrox, Euthyrox, Eutirox, Levothyrox) is a synthetic form of thyroxine derived from the thyroid gland. It functions via Thyroid Hormone Receptor Agonist mechanism of action. Levothyroxine Sodium is formulated as tablets for oral route of administration. Levothyroxine Sodium is indicated as therapy of hormone replacement or supplementation in patients with hypothyroidism of any etiology primary hypothyroidism resulting from functional deficit; primary atrophy of thyroid; total or partial ablation of the thyroid gland, with or without goiter and hypothyroidism secondary or tertiary. Levothyroxine Sodium was first approved in 1980 and is marketed globally in the US, Canada, Russia, France and Germany by several prominent pharma giants including Provell Pharmaceuticals LLC.